BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard Sells 1,577 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 1,577 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,425.00. Following the transaction, the chief marketing officer now owns 104,961 shares of the company’s stock, valued at approximately $2,624,025. This represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Todd Berard also recently made the following trade(s):

• On Monday, March 3rd, Todd Berard sold 424 shares of BioLife Solutions stock. The shares were sold at an average price of $25.46, for a total transaction of $10,795.04.
• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total value of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total transaction of $9,267.86.

BioLife Solutions Stock Performance

NASDAQ:BLFS opened at $25.06 on Friday. The firm’s fifty day simple moving average is $26.64 and its 200 day simple moving average is $25.51. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.18 billion, a PE ratio of -23.64 and a beta of 2.04. BioLife Solutions, Inc. has a 1 year low of $14.84 and a 1 year high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. The company had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the previous year, the company earned ($0.21) EPS. On average, sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on BLFS. Northland Securities increased their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. Benchmark restated a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. KeyCorp raised their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Finally, HC Wainwright upped their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.86.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds have recently bought and sold shares of the company. State Street Corp increased its holdings in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after acquiring an additional 18,473 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in BioLife Solutions by 40.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock valued at $487,000 after buying an additional 5,638 shares during the last quarter. Barclays PLC lifted its position in shares of BioLife Solutions by 20.1% during the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after purchasing an additional 10,803 shares in the last quarter. Finally, D.A. Davidson & CO. purchased a new position in shares of BioLife Solutions in the 3rd quarter worth approximately $1,018,000. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.